A single infusion of zoledronic acid 5 mg (ZOL) is significantly more effective than daily oral risedronate 5 mg (RIS) in increasing bone mineral density (BMD) of the lumbar spine (LS), hip, femoral neck and trochanter in patients with glucocorticoid-induced osteoporosis (GIO)